With the end of the year approaching, I’m reflecting on the pCPA’s work in 2025 and everything that we accomplished during a very exciting 12 months. I joined the organization as CEO in February, which coincided with the launch of our new visual brand identity. Looking back, this has become a symbol for how the pCPA has changed and evolved, with many milestones achieved throughout the year.
We expanded our team and saw record-high negotiation volumes — at the peak in August, there were 49 active negotiations. We passed the 750 mark for the total number of agreements reached, while improving our negotiation timelines to a record low of 6.5 months.
I’m especially proud that this is something we achieved while supporting national priorities and navigating big political and social changes to the pharmaceutical landscape.
Truly, 2025 was a year of big progress and big steps forward for the pCPA. Now, I’m looking toward ending the year on another high note with the launch of our new and revised expedited negotiation pathways, the Early Negotiation Process and the Targeted Negotiation Process.
I’m also excited about the new frontiers we’ll navigate in 2026, including implementing our first strategic plan developed as a standalone organization.
My heartfelt thanks go out all of you — colleagues, members, patient groups, clinicians, manufacturers — for your hard work, trust, and collaboration.
Wishing you all a joyful holiday season and a happy new year!